SCD Development

SCD Development is a biotechnology company focused on the research and development of therapies for sickle cell disease (SCD). The company is best known for its foundational work on pharmaceutical-grade L-glutamine, which led to the FDA approval of Endari to reduce acute complications of sickle cell disease in both adult and pediatric patients. Founded by Dr. Yutaka Niihara, SCD Development operates as a key research and intellectual property entity closely affiliated with Emmaus Life Sciences. The company's approach centers on addressing oxidative stress in red blood cells by increasing the NAD redox potential, providing a critical treatment option for a historically underserved patient population. SCD Development continues to support the clinical and commercial expansion of its lead therapy in global markets.